GlobalData reported on Model Medicines’ lead antiviral candidate, MDL-001, following an update presented at the Biocom Global Partnering Conference in California. The article positions MDL-001 as a potential first-in-class oral direct-acting antiviral, noting its reported preclinical activity across respiratory viruses including RSV, SARS-CoV-2, and influenza; hepatic viruses including HCV, HBV, and HDV; and gastrointestinal viruses including norovirus. The feature also discusses MDL-001’s potential relevance for pandemic preparedness, early empiric treatment, and government stockpiling strategies, while noting that the program remains in preclinical development as it advances toward IND submission and clinical evaluation.